Hosted on MSN
GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet
Just days after completing a $10.6bn takeover of lung cancer biotech Nuvalent, GSK is already reaping the rewards with Jideytro (zidesamtinib) having gained US approval in ROS1-positive non-small cell ...
Buy
GSK launches tender offer for USD10.6 billion purchase of Nuvalent
(Alliance News) - GSK PLC on Wednesday said it has launched the tender offer for its previously announced acquisition of US-based cancer drug developer Nuvalent Inc for USD10.6 billion. The ...
coincentral
Nuvalent (NUVL) Stock Jumps 39% After GSK’s $10.6 Billion Takeover Bid
Nuvalent (NUVL) stock jumped 39% after GSK agreed to acquire the cancer drug developer for $10.6 billion at $124 per share, a 40% premium. GSK agreed to acquire Nuvalent for $10.6 billion in an ...
Wall Street Journal
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
GSK GSK-2.02%decrease; down pointing triangle agreed to buy U.S. cancer-drug developer Nuvalent for $10.6 billion, the British pharmaceutical company’s latest move to bolster its oncology business.
U.S. News & World Report
GSK Boosts Cancer Portfolio With $10.6 Billion Nuvalent Takeover
GSK Boosts Cancer Portfolio With $10.6 Billion Nuvalent Takeover By Bhanvi Satija and Yadarisa Shabong LONDON, June 9 (Reuters) - GSK has agreed to buy U.S.-listed cancer ⁠drug ⁠developer Nuvalent for ...
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
An impending loss of exclusivity for dolutegravir, GSK's foundational HIV franchise, threatens to erode operating profit ...